Literature DB >> 8806291

Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients.

J L Ruud Bosch1, J Groen.   

Abstract

BACKGROUND: Urge urinary incontinence in multiple sclerosis patients is usually due to detrusor hyperreflexia. Patients who do not respond to conservative measures such as anticholinergics, with or without clean intermittent catheterisation, are difficult to manage.
METHODS: We applied electrical stimulation to the S3 sacral spinal nerves with the aim of activating afferent somatic nerve fibres. Stimulation of these fibres can inhibit the micturition reflex. An S3 electrode coupled to a subcutaneously placed pulse generator was implanted in four women who had shown a good response during temporary stimulation via a percutaneously placed wire electrode. All patients were followed for at least 2 years.
FINDINGS: The number of leakage episodes decreased from a mean of 4 to 0.3 per 24 h. Two patients were completely dry. The hyperreflexia disappeared in one, improved in two, and got worse in one patient. The urodynamic result in the last patient may be explained by clinical progression of the multiple sclerosis.
INTERPRETATION: Chronic stimulation of the S3 sacral spinal nerve by an implantable neuroprosthesis is a promising treatment option for selected multiple sclerosis patients with refractory urge incontinence.

Entities:  

Mesh:

Year:  1996        PMID: 8806291     DOI: 10.1016/s0140-6736(96)04437-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  Sacral nerve stimulation for the management of voiding dysfunction.

Authors:  A K Das; M D White; P A Longhurst
Journal:  Rev Urol       Date:  2000

Review 2.  Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.

Authors:  Federica Puccini; Alka Bhide; Suzy Elneil; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2015-07-09       Impact factor: 2.894

Review 3.  Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.

Authors:  Samina Tahseen
Journal:  Int Urogynecol J       Date:  2018-01-04       Impact factor: 2.894

Review 4.  The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.

Authors:  A Tubaro; F Puccini; C De Nunzio; G A Digesu; S Elneil; C Gobbi; V Khullar
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

5.  Characterization and restoration of altered inhibitory and excitatory control of micturition reflex in experimental autoimmune encephalomyelitis in rats.

Authors:  Jean-Rodolphe Vignes; Mathilde S A Deloire; Klaus G Petry; Frédéric Nagy
Journal:  J Physiol       Date:  2006-10-26       Impact factor: 5.182

6.  Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.

Authors:  João Carlos Correia de Sa; Laura Airas; Emmanuel Bartholome; Nikolaos Grigoriadis; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 7.  Neuroprostheses to treat neurogenic bladder dysfunction: current status and future perspectives.

Authors:  Nico J M Rijkhoff
Journal:  Childs Nerv Syst       Date:  2003-12-05       Impact factor: 1.475

Review 8.  Choosing drug therapy for multiple sclerosis. An update.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

9.  Do Physical Therapy Interventions Affect Urinary Incontinence and Quality of Life in People with Multiple Sclerosis?: An Evidence-Based Review.

Authors:  Valerie Block; Monica Rivera; Marsha Melnick; Diane D Allen
Journal:  Int J MS Care       Date:  2015 Jul-Aug

Review 10.  Female neurogenic vesicourethral dysfunction: evaluation and management.

Authors:  Rebecca J McCrery; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2005-09       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.